Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Deferred Revenue (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Current Deferred Revenue for 9 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 49.45% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, down 49.45% year-over-year, with the annual reading at $9.5 million for FY2025, 49.45% down from the prior year.
  • Current Deferred Revenue hit $9.5 million in Q4 2025 for Protagonist Therapeutics, down from $14.2 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $40.9 million in Q2 2024 to a low of $3000.0 in Q3 2023.
  • Historically, Current Deferred Revenue has averaged $9.6 million across 5 years, with a median of $5.8 million in 2021.
  • Biggest five-year swings in Current Deferred Revenue: crashed 98.57% in 2022 and later skyrocketed 656433.33% in 2024.
  • Year by year, Current Deferred Revenue stood at $1.6 million in 2021, then tumbled by 95.69% to $69000.0 in 2022, then tumbled by 95.65% to $3000.0 in 2023, then surged by 629600.0% to $18.9 million in 2024, then crashed by 49.45% to $9.5 million in 2025.
  • Business Quant data shows Current Deferred Revenue for PTGX at $9.5 million in Q4 2025, $14.2 million in Q3 2025, and $14.7 million in Q2 2025.